Compare Home Depot Inc (HD) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Neurocrine Biosciences Inc — how do they compare? Home Depot Inc trades at $331.12 (market cap $332.08B), while Neurocrine Biosciences Inc trades at $177.33 (market cap $17.40B). The key difference: Home Depot Inc is far larger — about 19.1× Neurocrine Biosciences Inc's market cap, and Home Depot Inc pays a 2.8% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| HD | NBIX | |
|---|---|---|
Market Cap | $332.08B | $17.40B |
Sector | Consumer Cyclical | Health |
52-Week High | $423.42 | $180.55 |
52-Week Low | $297.51 | $123.10 |
Enterprise Value | $393.64B | $16.49B |
Dividend Yield | 2.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $331.84, down 2.07% on the day, as the stock faces technical bearish pressure with mixed earnings performance. The company reported Q1 2026 EPS of $3.43, beating expectations, but missed in Q3 2025. Revenue reached $159.51B in 2025 with strong profitability metrics including 8.41% net margin and 128.38% ROE. Recent institutional activity shows mixed positioning while analyst consensus remains bullish with a $370.59 price target.
HD presents a compelling long-term investment case with strong fundamentals and analyst support, though near-term headwinds include weakening big-ticket demand and margin pressure. The stock's current discount to consensus target offers potential upside, but investors should monitor housing market trends and consumer spending patterns that impact home improvement demand.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
